ArticleJournal of the American Chemical Society2017
Overcoming the Limits of Hypoxia in Photodynamic Therapy: A Carbonic Anhydrase IX-Targeted Approach.
Article in Journal of the American Chemical Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 319 citations in OpenAlex.
- Tumor microenvironment-rearranging Nanoassemblies overcome angiogenesis-immunotherapy resistance to potentiate osteosarcoma treatment.Materials today. Bio · 2026Article
- Perilipin-2-Anchored Lipid Droplet-Targeting Phototheranostics.Angewandte Chemie (International ed. in English) · 2026Article
- Special Issue "Molecular Advances in Oncological Photodynamic Therapy".International journal of molecular sciences · 2026Article
- Synergy between photonics and biological approaches-A review of combination therapies for cancer theranostics.APL bioengineering · 2025Review
- Near-Infrared Conjugated Macrocyclic BODIPYs for Photothermal Cancer Therapy.Angewandte Chemie (International ed. in English) · 2025Article
- Multifunctional Liposomes: Smart Nanomaterials for Enhanced Photodynamic Therapy.Biomimetics (Basel, Switzerland) · 2025Review
- Hyperbaric Oxygen Regulates Tumor pH to Boost Copper-Doped Hydroxyethyl Starch Conjugate Nanoparticles Against Cancer Stem Cells.Exploration (Beijing, China) · 2025Article
- The Combination of Active-Targeted Photodynamic Therapy and Photoactivated Chemotherapy for Enhanced Cancer Treatment.Journal of biophotonics · 2025Review
- Dyad System of BOAHY-BODIPY Conjugates as Novel Photoswitchable Photosensitizers for Photodynamic Therapy.Journal of medicinal chemistry · 2025Article
- Self-healable and pH-responsive spermidine/ferrous ion complexed hydrogel Co-loaded with CA inhibitor and glucose oxidase for combined cancer immunotherapy through triple ferroptosis mechanism.Bioactive materials · 2025Article
- Near-infrared light-activatable iridium(iii) complexes for synergistic photodynamic and photochemotherapy.Chemical science · 2025Article
- Organelle-Specific Smart Supramolecular Materials for Bioimaging and Theranostics Application.Topics in current chemistry (Cham) · 2024Review
- Tuning singlet oxygen generation with caged organic photosensitizers.Nature communications · 2024Article
- Lutetium Texaphyrin-Celecoxib Conjugate as a Potential Immuno-Photodynamic Therapy Agent.Journal of the American Chemical Society · 2024Article
- Self-assembly-integrated tumor targeting and electron transfer programming towards boosting tumor type I photodynamic therapy.Chemical science · 2024Article
- Tumor acidification and GSH depletion by bimetallic composite nanoparticles for enhanced chemodynamic therapy of TNBC.Journal of nanobiotechnology · 2024Article
- A Bioorthogonal Antidote Against the Photosensitivity after Photodynamic Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Engineering tumor-oxygenated nanomaterials: advancing photodynamic therapy for cancer treatment.Frontiers in bioengineering and biotechnology · 2024Review
- Cancer Cell-Specific Fluorescent Prodrug Delivery Platforms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Interstitial Photodynamic Therapy of Glioblastomas: A Long-Term Follow-up Analysis of Survival and Volumetric MRI Data.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
A major challenge in photodynamic cancer therapy (PDT) is avoiding PDT-induced hypoxia, which can lead to cancer recurrence and progression through activation of various angiogenic factors and significantly reduce treatment outcomes. Reported here is an acetazolamide (AZ)-conjugated BODIPY photosensitizer (AZ-BPS) designed to mitigate the effects of PDT-based hypoxia by combining the benefits of anti-angiogenesis therapy with PDT. AZ-BPS showed specific affinity to aggressive cancer cells (MDA-MB-231 cells) that overexpress carbonic anhydrase IX (CAIX). It displayed enhanced photocytotoxicity compared to a reference compound, BPS, which is an analogous PDT agent that lacks an acetazolamide unit. AZ-BPS also displayed an enhanced in vivo efficacy in a xenograft mouse tumor regrowth model relative to BPS, an effect attributed to inhibition of tumor angiogenesis by both PDT-induced ROS generation and CAIX knockdown. AZ-BPS was evaluated successfully in clinical samples collected from breast cancer patients. We thus believe that the combined approach described here represents an attractive therapeutic approach to targeting CAIX-overexpressing tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.